Valuation: Sanofi

Market Cap 90.32B 103B 82.94B 77.34B 147B 9,840B 149B 999B 387B 4,826B 388B 380B 16,630B P/E 2026 *
11.3x
P/E 2027 * 10.4x
Enterprise Value 99.99B 114B 91.82B 85.63B 162B 10,894B 165B 1,106B 428B 5,343B 430B 420B 18,412B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.92x
Free-Float
89%
Yield 2026 *
5.66%
Yield 2027 * 5.99%
1 day+3.68%
1 week+3.25%
Current month+1.17%
1 month+0.84%
3 months-9.88%
6 months-10.51%
Current year-10.94%
1 week 41.27
Extreme 41.27
43.48
1 month 40.89
Extreme 40.89
45.24
Current year 40.89
Extreme 40.89
49.42
1 year 40.89
Extreme 40.89
52.68
3 years 40.89
Extreme 40.89
60.12
5 years 36.91
Extreme 36.91
60.12
10 years 36.81
Extreme 36.8101
60.12
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+3.68%+3.25% - - 103B
+1.86%+7.65%+55.77%+158.84% 1,082B
+3.57%+7.42%+69.09%+58.92% 633B
+3.99%+7.37%+36.87%+93.77% 461B
+2.80%-1.94%+26.41%+20.22% 339B
-0.83%+0.99%+41.71%+39.39% 301B
-0.52%+1.17%+31.98%+44.30% 292B
-1.78%+2.72%-25.42%-39.66% 225B
+3.55%+6.05%+26.04%+68.52% 202B
+4.21%+6.00%+17.72%+70.33% 163B
Average +1.58%+4.52%+31.13%+57.18% 411.08B
Weighted average by Cap. +1.33%+5.21%+41.74%+81.23%

Financials

2026 *2027 *
Net sales 47.12B 53.92B 43.26B 40.35B 76.49B 5,133B 77.78B 521B 202B 2,518B 202B 198B 8,676B 50.06B 57.28B 45.96B 42.87B 81.26B 5,454B 82.63B 553B 214B 2,675B 215B 210B 9,217B
Net income 8.4B 9.62B 7.72B 7.2B 13.64B 916B 13.88B 92.93B 36.01B 449B 36.12B 35.33B 1,548B 9.3B 10.65B 8.54B 7.97B 15.1B 1,014B 15.36B 103B 39.86B 497B 39.98B 39.11B 1,713B
Net Debt 9.67B 11.07B 8.88B 8.28B 15.7B 1,054B 15.97B 107B 41.45B 517B 41.57B 40.66B 1,781B 5.86B 6.7B 5.38B 5.02B 9.51B 638B 9.67B 64.78B 25.1B 313B 25.18B 24.63B 1,079B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change Volume
26-07-02 US$43.16 +3.68% 3,459,474
26-07-01 US$41.63 -2.41% 4,521,020
26-06-30 US$42.66 -1.77% 2,883,068
26-06-29 US$43.43 +1.12% 2,809,573
26-06-26 US$42.95 +2.75% 6,762,100
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
75.25EUR
Average target price
96.70EUR
Spread / Average Target
+28.51%

Quarterly revenue - Rate of surprise